Macquarie Group LTD Taysha Gene Therapies, Inc. Transaction History
Macquarie Group LTD
- $87.4 Billion
- Q1 2024
A detailed history of Macquarie Group LTD transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 8,066 shares of TSHA stock, worth $18,067. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,066Holding current value
$18,067% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding TSHA
# of Institutions
111Shares Held
109MCall Options Held
108KPut Options Held
158K-
Avoro Capital Advisors LLC New York, NY18.7MShares$41.8 Million0.65% of portfolio
-
Rtw Investments, LP New York, NY18.6MShares$41.6 Million0.86% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$20.2 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$13.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY5.17MShares$11.6 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $108M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...